Skip To Main Content
Christopher Barback on Muck Rack

Christopher Barback

As seen in: BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christopher

Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Neuronal Ndst1 depletion accelerates prion protein clearance and slows neurodegeneration in prion infection

|
By Daniel Sandoval, Christopher Barback, Patricia Aguilar Calvo, Adela Malik
| BioRxiv
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Open in Who Shared View Duplicates (700) Issue with article?

Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin

|
By Spencer T. Burton, Matthew Thompson, Robert Hennis, Christopher Barback
| American Chemical Society
We describe the design, synthesis, and antitumor activity of an 18 carbon α,ω-dicarboxylic acid monoconjugated via an ester linkage to paclitaxel (PTX). This 1,18-octadecanedioic acid-PTX (ODDA-PTX) prodrug readily forms a noncovalent complex with human serum albumin (HSA).
Open in Who Shared Issue with article?

Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin

|
By Spencer T. Burton, Matthew Thompson, Robert Hennis, Christopher Barback
| American Chemical Society
Harnessing human serum albumin (HSA) as a drug carrier in oncology is an established strategy aimed to improve dosing, safety, and efficacy.(1−4) HSA is the most abundant serum protein with myriad functions, including a central role in metabolic pathways as a transporter of long-chain fatty acids (LCFAs) and hydrophobic molecules, both natural and synthetic.(5−7) Recently, HSA and its endogenous ligands have gained interest for their roles in dysregulated metabolism tied to tumor growth.(8,9)...
Open in Who Shared Issue with article?
See all 3 articles